T0	Participants 40 86	clozapine-treated patients with schizophrenia:
T1	Participants 381 429	in clozapine-treated patients with schizophrenia
T2	Participants 487 539	trial, clozapine-treated patients with schizophrenia
T3	Participants 899 905	eight.
T4	Participants 906 943	Nineteen patients completed the study
T5	Participants 1040 1098	the rosiglitazone group (n=9) and the placebo group (n=10)
T6	Participants 1319 1367	in clozapine-treated patients with schizophrenia
T7	Participants 1536 1566	in patients with schizophrenia